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The insulin response of cultured human islets of Langerhans was measured at both mRNA and polypeptide 
levels in response to natural and pharmacological stimuli. We report a dosage dependent s imulation of 
both mRNA levels and insulin secretion by extracellular glucose, and present evidence that islet responsive- 
ness can be divided into two temporal phases: an early response, apparently under post-transcriptional 
control, and a late phase in which insulin messenger accumulates. A though glucose effects in man are simi- 
lar to rodents, there are important differences, especially with respect to modulation of glucose stimulation 
by activators offl-cell protein kinases. 
Insulin gene expression; Preproinsulin mRNA; Insulin secretion; cyclic AMP; Protein kinase; (Human pancreatic slet) 
1. INTRODUCTION 
Co-ordinated regulation of insulin gene expres- 
sion, biosynthesis and release is essential to main- 
tain the fuel sensor function of the pancreatic 
/~-cell. Extracellular glucose is the major 
physiological regulator of both insulin biosynthesis 
and release. However, in contrast to the many 
studies on insulin release, there have been few on 
the molecular mechanisms regulating glucose 
stimulation of insulin biosynthesis and these have 
been entirely restricted to rodent models. It is im- 
portant that these observations be extended to 
man. Although data are necessarily fragmentary, 
human insulin secretion is essentially similar to ro- 
dent models [1]. However, the molecular basis of 
insulin gene expression and biosynthesis is 
unknown in man, which restricts our under- 
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standing of a possible contribution of defects at 
this level to the pathophysiology of diabetes 
mellitus. 
The clonal /8-cell line HIT-T15 [2] is derived 
from the Syrian hamster which has, like humans, 
a single insulin gene [3]. In contrast, rats and mice 
possess two non-allelic insulin genes [4]. We have 
recently demonstrated a dose-dependent regulation 
of HIT-T15 insulin gene expression by glucose, 
and this may be in part transcriptional [5], and is 
modulated by activators of H-cell protein kinases. 
In the .present study we have used similar tech- 
niques to address, for the first time, the molecular 
nature of control mechanisms regulating insulin 
gene expression in the human H-cell. We 
demonstrate hat regulation of insulin gene expres- 
sion is essentially similar in man and rodent in 
terms of responsiveness to glucose stimulation. 
However, it is apparent that there are differences 
between man and rodent with respect to both 
modulation of glucose stimulation by activators of 
H-cell protein kinases, and also in responsiveness to 
pharmacological stimuli. 
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2. EXPERIMENTAL 
2. I . Mater ia l s  
Culture medium RPMI 1640, fetal calf serum 
and tissue culture dishes (Nunclon) were purchased 
from Gibco (Paisley, Scotland); [32p]dATP (spec. 
act. > 3000 Ci/mmol) from Amersham (Bucks, 
England); the phorbol ester, 12-O-tetradecanoyl- 
phorbol 13-acetate (TPA), from PL Biochemicals 
(Northampton, England) and forskolin from 
Calbiochem (Cambridge, England). X-ray film 
was bought from Kodak (Liverpool, England). All 
additional reagents were purchased from Sigma or 
British Drug Houses (Poole, Dorset, England). 
2.2. Methods  
Human islets of Langerhans were isolated from 
pancreata of renal transplant donors by col- 
lagenase digestion as described [6]. Freshly isolated 
islets (approx. 1000/dish) were preincubated at 
37°C in RPMI 1640 supplemented with glucose (11 
mM), 10% (v/v) fetal calf serum and antibiotics 
for 48 h prior to further manipulation. Subse- 
quently, insulin secretion and preproinsulin (ppI) 
mRNA were assayed following incubation in 
RPMI 1640 without glucose, supplemented as 
listed in section 3. All data are derived from 
duplicate or triplicate preparations of human pan- 
creas. Insulin secretion was measured by radioim- 
munoassay [7]. ppI mRNA was assayed by 
Northern hybridization to human insulin cDNA, 
autoradiography and densitometry. The human i - 
sulin cDNA probe (pchinsl-19/HB101) [8] was a 
gift from Dr G.I. Bell (Chiton Corp., Emeryville, 
CA, USA) and was labelled with [32p]dATP by 
nick-translation [9]. Total RNA was extracted by 
guanidinium isothiocyanate, s parated on agarose- 
formaldehyde g ls, blotted to nitrocellulose filters 
Fig.1. Human islets of Langerhans in tissue culture. Islets were isolated by collagenase digestion and cultured for 48 
h in RPMI 1640. Magnification x 190. 
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and hybridized essentially as we have described for 
HIT-T15 cells [5]. ppI mRNA levels were subse- 
quently normalised against a constitutively ex- 
pressed mRNA (glyceraldehyde-3-phosphate 
dehydrogenase, GAP-DH) by rehybridization to 
GAP-DHcDNA as described [10]. 
3. RESULTS AND DISCUSSION 
Following isolation, islets were maintained in 
culture for 48 h prior to further analysis. This was 
a necessary precaution taken to extract optimal in- 
formation from scarce tissue, since freshly isolated 
rat islets demonstrate (i) acute rapid losses of ppI 
mRNA and impaired proinsulin biosynthesis, re- 
quiring a recovery period in tissue culture of up to 
24 h [11,12], and (ii) a refractory secretory 
response to acetylcholine, which is restored only 
after at least 44 h in culture [13]. During the prein- 
cubation period, a majority of islets adhered firm- 
ly to the culture dish, facilitating subsequent 
manipulation (fig.l). After preincubation, islets 
were incubated in the presence (2-20 mM) or 
absence of glucose for 24 h. Northern hybridiza- 
tion of total RNA with human ppI cDNA revealed 
a 0.5 kb transcript, consistent with that expected of 
mature ppI mRNA, and similar to insulin 
messenger present in both primary human in- 
sulinoma [5] and post-mortem extracts of whole, 
frozen pancreas [14]. Glucose (2-20 mM) induced 
a 3.5-fold dose-dependent s imulation of human 
ppI mRNA concomitant with 5-fold stimulation of 
insulin secretion (fig.2a). Both ppI mRNA and in- 
sulin secretion demonstrated threshold levels of 
between 2 and 5 mM glucose and maximal rates of 
stimulation between 5 and 10 mM glucose. In con- 
trast, between 0 and 2 mM glucose, basal insulin 
secretion rates were maintained whereas ppI 
mRNA levels fell by 35°7o. These results indicate 
that, at physiological concentrations of ex- 
tracellular glucose, there is parallelism between ppI 
mRNA content and insulin secretion. However, 
the uncoupling between ppI mRNA and insulin 
secretion at low levels of extracellular glucose in- 
dicates that post-transcriptional control may also 
occur. 
Next, we investigated the kinetics of stimulation 
induced by high (20 mM) relative to low (2 mM) 
glucose for 4, 12 or 24 h following preincubation 
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Fig.2. Effect of glucose on ppI mRNA and insulin secre- 
tion (a) Dose-dependent stimulation of ppI mRNA and 
insulin secretion by glucose. Islets were preincubated for 
48 h, then exposed to glucose (2-20 mM) for a further 
24 h. ppI mRNA was determined by densitometry of
Northern blots and was normalised against GAP-DH 
mRNA; insulin secretion was measured by radioim- 
munoassay. Data are representative of triplicate 
preparations of human pancreas. (b) Time course of 
glucose stimulation of ppI mRNA. Islets were prein- 
cubated for 48 h, then exposed to high (20 mM) and low 
(2 mM) glucose for 4, 12, or 24 h. ppI mRNA was deter- 
mined as above and is expressed as stimulation by high 
relative to low glucose. Data are representative of
duplicate preparations of human pancreas. 
(fig.2b). After 4 h there was no stimulation of ppI 
mRNA accumulation, and only 1.5-fold stimula- 
tion after 12 h, compared with a 3.5-fold increase 
after 24 h. In contrast, insulin secretion was 
stimulated 5-fold at all time points (not shown). 
This suggests that in culture, the immediate 
response of islets to glucose stimulation is 
predominantly secretory, with demands for insulin 
being met through depletion of existing stores of 
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proinsulin and/or ppI mRNA. This clearly allows 
for a short-term response which is both rapid and 
flexible, since transcription de novo must in- 
evitably take longer. 
In the absence of sufficient experimental 
material, direct analysis of insulin gene transcrip- 
tion by isolated human B-cell nuclei is not yet prac- 
ticable. However, early observations inferring a 
regulatory role for glucose relied on the use of in- 
hibitors [15] and were subsequently confirmed by 
the development of direct assays for insulin 
messenger [16]. By using specific inhibitors we can 
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Fig.3. Modulation of glucose-stimulated ppI mRNA and insulin secretion by inhibitors of RNA and protein synthesis. 
Islets were preincubated for 48 h, then exposed to agents as listed for a further 24 h. ppI mRNA was determined by 
densitometry of Northern blots and was normalised against GAP-DH mRNA; insulin secretion was measured by 
radioimmunoassay. Data are representative of duplicate preparations of human pancreas. (a) Autoradiograph 
demonstrating Northern blot analysis of ppI mRNA; lane l, 2 mM glucose (2G); lane 2, 20 mM glucose (20G); lane 
3, 2G + 20 ttg/ml cycloheximide (C) + l/xg/ml actinomycin D (A); lane 4, 20G + C; lane 5, 2G + C; lane 6, 20G + C + A; 
lane 7, 20G + A. (b) Relative stimulation of ppI mRNA and insulin secretion. 
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now present evidence which suggests that more 
long-term regulation of human insulin gene expres- 
sion by glucose is mediated at both transcriptional 
and post-transcriptional levels. Incubation of 
human islets with 20/zg/ml cycloheximide (which 
inhibits protein synthesis by over 90% in rat islets 
[15]) induced marked augmentation f ppI mRNA 
in the presence of both high and low glucose con- 
centrations (fig.3), suggesting that synthesis of a 
negative peptide modulator of transcript levels 
(perhaps insulin itself), feeds back to regulate 
mRNA abundance via modulation of messenger 
half-life or transcription, or even both. The RNA 
polymerase inhibitor actinomycin D, inhibited 
cycloheximide-induced ppI mRNA accumulation 
at both high and low glucose by 43% and 32°70, 
respectively, suggesting some transcriptional in- 
volvement. In addition, glucose-stimulated ppI 
mRNA accumulation was also inhibited by 25°70 in 
the presence of actinomycin D. The effects of these 
inhibitory compounds at the concentrations u ed 
are unlikely to reflect impaired viability since in- 
sulin secretory rates were not affected. This latter 
observation also suggests that the initial secretory 
requirements of the /~-cell are met through 
mobilisation of proinsulin stores and are not 
restricted by mRNA availability. 
The effects of activators of/3-cell protein kinases 
ppl mRNA 
tin- 
on glucose-stimulated effects were also in- 
vestigated (fig.4). The adenylate cyclase activator 
forskolin provoked a 1.5-fold potentiation of the 
effects of glucose on ppI mRNA accumulation a d 
insulin secretion. This suggests that positive con- 
trol of glucose-regulated insulin gene activity in 
man may be mediated in part by /3-cell cAMP, 
which activates cAMP-dependent protein kinase 
(cAMP-PrK). In contrast, there was an inhibition 
of' human insulin messenger accumulation by ac- 
tivators of Ca 2 ÷-phospholipid-dependent protein 
kinase (protein kinase C-PKC). The phorbol ester 
TPA, which activates/3-cell PKC directly [17], in- 
hibited glucose-stimulated ppI mRNA accumula- 
tion by 50%, despite inducing a2-fold potentiation 
in the rate of insulin secretion. Furthermore 
bradykinin, which activates PKC indirectly (via 
phosphoinositide turnover) in human fibroblasts 
[18], inhibited glucose-stimulated ppI mRNA 
without affecting insulin secretion. This indicates a 
further level of regulation of human insulin 
biosynthesis: negative modulation of insulin gene 
expression by PKC. However, it also demonstrates 
an important difference between man and rodent, 
because, in contrast, our previous studies with 
TPA in HIT-T15 ceils [5] have indicated positive 
modulation of insulin gene expression by PKC. 
Proinsulin biosynthesis is regulated by a variety 
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Fig.4. Modulation and specificity of glucose-stimulated ppI mRNA and insulin secretion. Islets were preincubated for 
48 h, then exposed for a further 24 h to either (i) agents known to affect/~-cell protein kinase or (ii) metabolisable sugars 
other than glucose, ppl mRNA was determined by densitometry of Northern blots and was normalised against GAP-DH 
mRNA; insulin secretion was measured by radioimmunoassay. Data are representative of duplicate preparations of 
human pancreas. 
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of additional agents in rodents [19]. The specificity 
of glucose regulation in humans was therefore con- 
sidered in relation to effects of other metabolisable 
sugars'. At equivalent concentrations (10 mM), 
glyceraldehyde proved an even more potent 
stimulator of human ppI mRNA than glucose. In 
contrast, mannose was ineffective, although both 
sugars induced a 3-fold stimulation of insulin 
secretion. Although these effects are unlikely to be 
of physiological significance, the failure of man- 
nose to affect human insulin messenger was unex- 
pected because, in rat islets, it parallels the effects 
of glucose on both insulin secretion and biosyn- 
thesis (as measured by radio-labelled leucine incor- 
poration) [19]. A comprehensive survey of agents 
affecting human insulin biosynthesis at a 
molecular level is clearly essential to evaluate the 
usefulness of rodent models. 
These studies demonstrate a dose-dependent 
stimulation of human insulin gene expression by 
extracellular glucose, the major physiological 
regulator of insulin biosynthesis and release. In the 
short-term, a pool of stored proinsulin and/or 
unused mRNA allows a very rapid and flexible 
response, whereas in the long-term transcriptional 
and post-transcriptional controls become impor- 
tant. In addition, pharmacological stimulation was 
effected by glyceraldehyde. The effects of ex- 
tracellular glucose are ssentially similar to those 
previously reported in rodents [5,11,12,20], as is a 
possible second messenger role for cAMP [5,21, 
22]. However, there were differences between man 
and rodent with respect o both the effects of ac- 
tivators of PKC and also the specificity of glucose 
stimulation. These differences may represent im- 
portant limitations of rodent models and require 
delineation. 
In the rodent ~-cell, cAMP regulates insulin 
secretion by modulating cAMP-PrK activity 
[23,24]. In addition, our laboratory has previously 
shown cAMP-PrK phosphorylation in human 
islets in response to glucose stimulation [25], and 
this represents a possible site for positive control of 
insulin gene expression in man. Moreover, the ef- 
fects of forskolin in human islets essentially 
parallel those we have previously reported in HIT- 
TI5 cells [5]. Therefore, HIT-T15 cells may pro- 
, ~de sufficient experimental material to allow iden- 
tiI:cation of either insulin gene sequences or
related protein substrates associated with regula- 
tion of gene activity mediated by cAMP-PrK 
phosphorylation. 
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